Soleno Therapeutics (SLNO) closed out FY 2025 with Q4 revenue of US$91.7 million and basic EPS of US$0.81, alongside trailing twelve month revenue of US$190.4 million and EPS of US$0.40 that mark a clear swing from earlier quarterly losses. Over the past four reported quarters, revenue has moved from US$0 in Q1 2025 to US$32.7 million in Q2, US$66.0 million in Q3 and US$91.7 million in Q4. Basic EPS shifted from a loss of US$0.95 in Q1 to a profit of US$0.49 in Q3 and US$0.81 in Q4, underscoring a sharp turn in profitability and a margin profile that is still settling as the business scales.

See our full analysis for Soleno Therapeutics.

With the headline numbers on the table, the next step is to see how this rapid shift in revenue and EPS lines up with the widely followed narratives around Soleno Therapeutics's growth, risk profile and long term earnings potential.

Trailing 12 Months Swing Into Profit

• On a trailing 12 month basis to Q4 2025, Soleno moved from a loss of US$198.2 million and EPS of US$4.65 loss at Q1 to net income of US$20.5 million and EPS of US$0.40 by Q4, alongside revenue rising from US$0 to US$190.4 million over the same window.
• Bulls point out that this shift to profitability lines up with analysts expecting earnings to grow about 36.2% per year and revenue about 31.4% per year. However, the journey there has included a US$5.5 million one off loss and multi year losses, so investors need to weigh how durable this early profit phase really is against those past results and the still evolving margin profile.

Bulls argue that the rapid move into the black could be the first chapter of a much bigger story for VYKAT XR and Soleno overall, and they lay out what that upside path might look like in more detail in the 🐂 Soleno Therapeutics Bull Case

Margin Shift Versus Bear Concerns

• Quarterly net income moved from a loss of US$43.8 million in Q1 2025 to a profit of US$42.9 million in Q4, while Basic EPS went from a US$0.95 loss to a US$0.81 profit over the same period, indicating a large swing in reported profitability even though the last 12 months still include a US$5.5 million one off loss.
• Bears focus on the risk that higher operating expenses, payer pressure and early treatment discontinuations could squeeze profits. They also note that earnings over the past five years averaged a 34.8% decline each year, which supports that concern to some degree. At the same time, the latest positive trailing result and the sharp quarterly move into profit mean those worries are being tested by fresher data that looks very different from the historical trend.

Skeptics warn that if costs climb faster than new revenue or if discontinuations stay elevated, the recent profit could prove fragile, so it is worth seeing how those concerns are laid out in the 🐻 Soleno Therapeutics Bear Case

High P/E And DCF Gap

• The stock trades on a trailing P/E of about 133.7x against a DCF fair value estimate of roughly US$440.77 per share and a current share price of US$52.95. This indicates that the market is assigning a very high multiple on reported earnings while the provided DCF model points to a very large gap between price and estimated intrinsic value.
• What stands out for both bullish and bearish narratives is this tension between a very high P/E relative to peer and biotech industry averages and the cited DCF fair value. Bulls can point to the DCF gap and strong growth forecasts to argue that the premium multiple is justified, while bears can highlight that such a lofty P/E leaves little room for earnings hiccups, even though the most recent 12 month profits sit on top of a history of losses and include a one off charge.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Soleno Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of early profits, a high P/E, and both clear risks and rewards, it helps to look past the headlines and into the details yourself, then weigh the 3 key rewards and 3 important warning signs

See What Else Is Out There

Soleno's early profitability still sits on top of years of earnings decline, a recent one off loss and a very high P/E that leaves little room for setbacks.

If that mix of fragile profits and elevated valuation makes you cautious, compare it with companies screened for stronger fundamentals and compelling prices through the 51 high quality undervalued stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.